![]() |
|
ResearchNitric Oxide (NO) Nitric Oxide Synthase (NOS) NOS Enzymes
Excess NO in the central nervous system has been implicated in pain sensations caused by migraine, nerve injury and neuropathic pain. Therefore, inhibition of nNOS has the potential to be beneficial in controlling these pain states, and NeurAxon is the first company to have developed and tested in human clinical trials a product candidate possessing selective nNOS inhibition. Scientific Articles About NOS2007 Jain K, “Nitric Oxide Therapeutics, Markets and Companies” Jain PharmaBiotech July 2007 Maddaford, S. et al, “Emerging Frontiers of Designed Multiple Ligands. Rationale Design of Dual Action Nitric Oxide Synthase Inhibitors with 5HT Agonism for the Treatment of Migraine” CSC2007 Abstract, Winnipeg Patman, J. et al, “Novel 2-aminobenzothiazoles as selective neuronal nitric oxide synthase inhibitors” Biorganic Medicinal Chemistry Letters 2007 May 1;17(9):2540-4. Epub 2007 Feb 8 2006 Patman, J. et al, “Novel Aminobenzothiazole Nitric Oxide Synthase Inhibitors. Applications in the Treatment of Central Nervous System Disorders” CSC2006 Abstract, Halifax Patman J. et al, “Novel neuronal Nitric Oxide Synthase (nNOS) Inhibitors in Models of Chronic Pain” CSC2006 Abstract, Halifax 2005 and earlier Afridi S, Kaube H and Goadsby PJ, “Occipital activation in glyceryl trinitrate induced migraine with visual aura” J. Neurol. Neurosurg. Psychiatry 2005;76;1158-1160 doi:10.1136/jnnp.2004.050633 van der Kuy P, Lohman J, “The role of nitric oxide in vascular headache” Pharm World Sci 2003; 25(4): 146-151 Thomsen L, Olesen J, “Nitric Oxide Theory of Migraine” Clinical Neuroscience 1998 |
|